There are two kinds of people in the world, says Brent Vaughan — those who prefer to make incremental changes with a lower likelihood of failure, and those who aspire to fix (seemingly) intractable problems that have stymied others. Brent falls in the latter category. A serial entrepreneur, former venture capitalist, and current CEO of Cognito Therapeutics (a DTx company that specializes in neurodegenerative diseases), Brent is also uniquely positioned to evaluate the future of next generation digital therapeutics.
Brent and Eugene talk about the differences between prescription and business-to-consumer DTx, the importance of engaging patients and users early on in the development of novel products, and the exciting potential of translational DTx solutions. Eugene’s podcast partner, Brian Dolan, also pops in with a question.
>>Click here to read the transcript
Guest Links and Resources:
Connect with Brent Vaughan: LinkedIn
Visit Cognito Therapeutics: Twitter | LinkedIn | Facebook | Website
Host Links and Resources:
Follow Eugene's journey of writing his first book: Hard Pill to Swallow
Subscribe to Exits & Outcomes
HealthXL: Website | Twitter | Join an Event
Follow Digital Health Today:
Browse Episodes | Twitter | LinkedIn | Facebook | Instagram
Follow Health Podcast Network:
Browse Shows | LinkedIn | Twitter | Facebook | Instagram
Digital Health Today is made possible by the support of our sponsors. Thank you to:
Ep10: Leveraging Novel Technologies to Meet Unmet Medical Needs - Brent Vaughan CEO, Cognito Therapeutics